Program

17 January 2020

09:00 - 09:15 Opening and Welcome Session
Fink, G. (Cologne/DE)
Klussmann, J.P. (Cologne/DE)
   
09:15 - 10:45
Chair
Session 1: Tumor immunology I
Wollenberg, B. (München/DE), Hoffmann, T. (Ulm/DE)
09:15
IS 1
Wollenberg, B. (München/DE):
New targets in immune oncology
09:35
IS 2
Laban, S. (Ulm/DE):
New lessons learned from clinical trials in immune oncology
09:55
IS 3
Muller, L. (Basel/CH):
Tumor derived exosomes in HNSCC
10:15
OP 1
The Oral Microbiome: current knowledge and future perspectives
Hussain, T., Lang S. (Essen/DE)
10:25
OP 2
Immunosenescence – age related changes in T lymphocytes of patients with head and neck squamous cell carcinoma
Schuler P.J., Jeske S.S., Doescher J., Theodoraki M.N., Laban S., Brunner C., Wigand M.C., Hoffmann T.K. (Ulm/DE)
10:35
OP 3
PD-1 / PD-L1 checkpoint Inhibition increases the cytotoxicity of NK cells against nasopharyngeal carcinoma cells in the context of chemotherapy
Kontny U., Makowska A., Meier S., Shen L. (Aachen/ DE), Baloche V., Busson P. (Villejuif/FR)
   
10:45 - 11:00 Coffee break
   
11:00 - 12:30
Chair
Session 2: Tumor signatures and personalized approaches
Dietz A. (Leipzig/DE), Muller L. (Basel/CH)
11:00
IS 4
George, J. (Cologne/DE):
Functional genomics
11:20
IS 5
Saintigny, P. (Lyon/FR):
Personalized approaches to the treatment of HNSCC - prevention to treatment
11:40
IS 6
Mehanna, H. (Birmingham/UK):
Prognosis and treatment prediction of OPC beyond HPV - the predict and correlate signatures
12:00
OP 4
Personalized target prediction by functional kinome profiling for HNSCC
Kriegs M., Bußmann L., Hoffer K., Münscher A., Rothkamm K., Betz C.S. (Hamburg/DE)
12:10
OP 5
CD44v6 as a new target for CAR T-cell immunotherapy in head and neck squamous cell carcinoma (HNSCC)
Scheckenbach K., Schulte E., Haist C., Bister A., Hanenberg H., Wiek C. (Düsseldorf/DE)
12:20
OP 6
Characterization of the immunogenic tumor microenvironment (TME) of subcutaneous and orthotopic grown head and neck squamous cell carcinoma in an immunocompetent mouse model
Brand M., Krüger J., Greve J., Theodoraki M.N., Döscher J., Laban S., Schuler P.J., Hoffmann T.K., Brunner C. (Ulm/DE)
   
12:30 - 13:30 LUNCH
   
13:30 - 15:00
Chair
Session 3: Tumor cell signalling
Speel, E.-J. (Maastricht/NL), Gires, O. (Munich/DE)
13:30
IS 7
Hess, J. (Heidelberg/DE):
Oncogenic signalling pathways in HNSCC
13:50
IS 8
Mandic, R. (Marburg/DE):
Mutation signature of P53 and impact on cell cycle
14:10
IS 9
Lai, S. (Houston, TX/US):
Disruption of TP63-miR-27a* regulation by mutant TP53 promotes HNSCC progression
14:30
OP 7
Adenosine receptor 2B activity promotes autonomous growth, migration as well as vascularization of head and neck squamous cell carcinoma cells
Brunner C., Mahr A., Wilkat M., Bast H., Drees, R., Dünser J., Azoitei N., Frank F., Pscheid R., Greve J., Theodoraki M.N., Döscher J., Laban S., Schuler P.J., Hoffmann T.K. (Ulm/DE)
14:40
OP 8
Resolving the transcriptomic makeup of the head and neck squamous cell carcinoma tumor microenvironment (HNSCC TME) using single cell RNA sequencing (scRNAseq)
Kürten C.H.L., Lang S. (Essen/DE), Kulkarni A., Vujanovic L., Bruno T., Cillo A.R., Ferris R.L. (Pittsburgh/USA)
14:50
OP 9
Growth Factor Receptor Expression in HNSCC
Deuss E. (Essen/DE), Stauber R. (Mainz/DE), Künzel J. (Regensburg/DE)
   
15:00 - 15:15 Coffee break
   
15:15 - 16:45
Chair
Session 4: HPV-related OPSCC
Wittekindt, C. (Dortmund/DE), Bussu, F. (Sassari/IT)
15:15
IS 10
Bussu, F. (Sassari/IT):
HPV as a marker for molecular characterization in head and neck oncology
15:35
IS 11
Broglie Däppen, M. (Zürich/CH):
Prognostic models in HPV-associated HNSCC
15:55
IS 12
Lechner, M. (London/UK):
Molecular aspects, vaccination, awareness and early detection
16:15
OP 10
A subgroup of HPV-positive oropharyngeal squamous cell carcinoma with unfavorable prognosis shows oxidative stress signatures and a mesenchymal-like phenotype
Huebbers C.U., Siefer O.G., Drebber U., Odenthal M., Akgül B., Hufbauer M., Klussmann J.P. (Cologne/DE), Beutner D. (Göttingen/DE), Speel E.J.M. (Maastricht/NL)
16:25
OP 11
A lack of effectiveness in the ATM-orchestrated DNA damage response contributes to the enhanced radiation sensitivity of HPV-positive HNSCC cell lines
Rieckmann T., Köcher S., Zech H., Gatzemeier F., Krug L., Meyer F., Kriegs M., Betz C., Rothkamm K. (Hamburg/DE)
16:35
OP12
Ex-vivo slice cultures of HNSCC tissues confirm the DNA double-strand break repair defect of HPV-positive OPSCC
Zech H.B., Kriegs M., Köcher S., Mansour W., Möckelmann N., Busch C.J., Böttcher A., Petersen C., Betz C.S., Rothkamm K., Rieckmann T. (Hamburg/DE)
   
16:45 - 17:05
Chair
Session 5: Investigator Initiated Trials (IIT) in Head and Neck Oncology I
Wittekindt, C. (Dortmund/DE), Bussu, F. (Sassari/IT)
16:45
IS 13
Dietz, A. (Leipzig/DE):
IAG-KHT
   
17:05 - 18:00 Poster Session with Kölsch and Snacks
   
19:30 Social evening at the Chocolate Museum Cologne (open end)

18 January 2020

08:00 - 08:30
IS 14
Breakfast-Symposium
Grünwald, V. (Essen/DE):
Treatment paradigm and perspectives in HNSCC
   
08:30 - 09:40
Chair
Session 6: Salivary Glands
Guntinas-Lichius, O. (Jena/DE), Quaas, A. (Cologne/DE)
08:30
IS 15
Guntinas-Lichius, O. (Jena/DE):
Possibilities of prognostic risk assessment for malignant salivary gland neoplasms
08:50
IS 16
Vander Poorten, V. (Leuven/BE):
Overview of recent advances in diagnostics and therapy of salivary gland carcinoma
09:10
IS 17
Agaimy, A. (Erlangen/DE):
The emerging complexity of gene fusions landscape in salivary gland carcinomas
09:30
OP 13
Evaluating a Raman spectroscopy-based algorithm for distinguishing salivary gland cancer from benign lesions
Meyer T., Hartmann E., Steinke M., Hagen R., Scherzad A., Hackenberg S. (Würzburg/DE)
   
09:40 - 10:00
Chair
Poster Presentations and Poster Awards
Wollenberg, B. (München/DE), Klussmann, J.P. (Cologne/DE)
Jurors Hoffmann, T. (Ulm/DE),
Wollenberg, B. (München/DE)
   
10:00 - 10:15 Coffee break
   
10:15 - 11:55
Chair
Session 7: Liquid Biopsy and molecular imaging
Klussmann, J.P. (Cologne/DE), Lechner, M. (London/UK)
10:15
IS 18
Joosse, S.A. (Hamburg/DE):
Liquid biopsy: Is it ready for clinical use?
10:35
IS 19
Speel, E.-J. (Maastricht/NL):
Liquid biopsy in HNSCC
10:55
IS 20
Sharma, S.J. (Cologne/DE):
Molecular and genomic imaging
11:15
OP 14
Improved detection of promising epigenetic biomarkers for head and neck cancer in saliva
Hums A-B., Erler T., Jansen L., Stein M., Dürst M., Priese J., Guntinas-Lichius O., Schmitz M., Hansel A. (Jena/DE)
11:25
OP 15
CD44v3 emerges as a cancer stem cell marker on tumor derived exosomes in HNSCC patient's plasma
Theodoraki M.N., Schuler P.J., Brunner C., Hoffmann T.K. (Ulm/DE), Whiteside T.L. (Pittsburgh/USA)
11:35
OP 16
Characterization of circulating exosomes as biomarkers for therapy monitoring in Head and Neck cancer (HNSCC) patients
Hofmann L., Brunner C., Schuler P.J., Hoffmann T.K., Laban S., Theodoraki M.N. (Ulm/DE)
11:45
OP 17
Analysis of human papillomavirus (HPV) 16 early protein antibodies and identification of patients at high risk for HPV-driven oropharyngeal cancer in the prospective cohort of the Hamburg City Health Study
Busch C.-J., Rieckmann T., Betz C., Hoffmann A.-S.,
Jagodzinski A. (Hamburg/DE), Pawlita M., Viarisio D., Waterboer T. (Heidelberg/DE)
   
11:55 - 12:55 LUNCH
   
12:55 - 14:25
Chair
Session 8: Metastatic processes and CUP
Mehanna, H. (Birmingham/UK), Hess, J. (Heidelberg/DE)
12:55
IS 21
Gires, O. (Munich/DE):
Regulation of EMT and the role for the metastatic phenotype
13:15
IS 22
Holsinger, C. (Palo Alto/US):
A Modest Proposal: Evolving from CUP to T1-micro-p16 SCC of the oropharynx
13:35
OP 18
Upregulation of PD-L1 in lymph node metastases and recurrent tumors of OSCC
Moratin J., Metzger K., Hess J., Hoffmann J., Freudlsperger C. (Heidelberg/DE)
13:45
OP 19
Impact of the tumor microenvironment on lymphatic metastasis in oropharyngeal carcinomas determined by Phenoptics
Netzer C., Witte Paz H. (Göttingen/DE), Weigert A. (Frankfurt/DE), Beutner D. (Göttingen/DE)
13:55
OP 20
Extracapsular extension of neck nodes and absence of human papillomavirus 16-DNA are predictors of impaired survival in p16-positive oropharyngeal squamous cell carcinoma
Freitag J., Wald T., Kolb M., Dietz A., Wiegand S., Wichmann G. (Leipzig/DE)
14:05
OP 21
Organotypic co-cultures (OTC) as a novel 3D model for head and neck squamous cell carcinoma
Engelmann L., Thierauf J., Koerich-Laureano N.,
Stark H.J., Prigge E.S., Horn D., Freier K., Grabe N., Federspil P. (Heidelberg/DE), Rotter N. (Mannheim/DE), Plinkert P.K., von Knebel-Doeberitz M., Hess J., Affolter A. (Heidelberg/DE)
14:15
OP 22
Interferon-beta increases NK cell cytotoxicity against tumor cells in patients with nasopharyngeal carcinoma via tumor necrosis factor apoptosis-inducing ligand
Makowska A., Franzen S., Braunschweig T., Shen L., Denecke B. (Aachen/DE), Baloche V., Busson P. (Villejuif/FR), Kontny U. (Aachen/DE)

14:25 - 14:45 Coffee break
   
14:45 - 15:45
Chair
Session 9: Investigator Initiated Trials (IIT) in Head and Neck Oncology II
Wollenberg, B. (München/DE), Klussmann, J.P. (Cologne/DE)
14:45
IS 23
Simon, C. (Lausanne/CH):
EORTC
15:05
IS 24
Lai, S. (Houston, TX/US):
NRG-HN006: SNL vs END for early OSCC
15:25
IS25
Mehanna, H. (Birmingham/U.K.):
Common crimes in surgical research
15:45 - 16:35
Chair
Session 10: Tumor immunology II
Quaas, A. (Cologne/DE), Klussmann, J.P. (Cologne/DE)
15:45
OP 23
Immunological and metabolic characterization in HNSCC
Ugele I., Singer K., Wehrstein M., Dettmer K., Kapsreiter M., Symeou L., Bohr C., Kreutz M. (Regensburg/DE)
15:55
OP 24
Excessive biological ageing of neutrophils in HNSCC promotes tumor growth
Uhl B., Mittmann L., Schaubaecher J., Hennel R., Zuchtriegel G., Canis M., Gires O., Krombach F., Holdt L. (München/DE), Brandau S. (Essen/DE), Vogl T. (Münster/DE), Lauber K., Reichel C. (München/DE)
16:05
OP 25
Genetic and epigenetic landscape of the molecular immuno-signature in HNSCC
Feng B., Shen Y., Huang Q., Hostench XP., Plath M., Huber P., Zaoui K., Bieg M., Ishaque N., Eils R., Freier K. (Heidelberg/DE), Weichert W. (Munich/DE), Hess J. (Heidelberg/DE)
16:15
OP 26
Natural killer cells induce senescence in head and neck cancer
Hillebrand G., Feng B., Hess J. (Heidelberg/DE)
16:25
OP 27
Exhaustion of CD8+ T cells determines Trametinib efficacy in KRAS-mutated head and neck cancers
Elkabets M., Parsad M., Jagadeeshan M., Tzadok S., Novoplansky O., Cohen L. (Beer Sheva/IL)
   
16:35 - 16:40 Closing Session